Edition:
India

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

284.50DKK
9:29pm IST
Change (% chg)

kr.-10.15 (-3.44%)
Prev Close
kr.294.65
Open
kr.293.00
Day's High
kr.294.10
Day's Low
kr.284.30
Volume
2,252,869
Avg. Vol
2,298,511
52-wk High
kr.354.80
52-wk Low
kr.265.15

Latest Key Developments (Source: Significant Developments)

Novo Nordisk And Embark Enter Collaboration To Discover Obesity And Metabolic Disease
Friday, 2 Nov 2018 

Nov 2 (Reuters) - Novo Nordisk A/S ::SAYS EMBARK AND NOVO NORDISK ENTER COLLABORATION TO DISCOVER NOVEL THERAPEUTICS FOR OBESITY AND METABOLIC DISEASE.  Full Article

Aeterna Zentaris Announces Novo Nordisk To Acquire Rights To Macrilen In U.S. And Canada
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS ANNOUNCES NOVO NORDISK TO ACQUIRE RIGHTS TO MACRILEN™ IN UNITED STATES AND CANADA.AETERNA ZENTARIS INC - NOVO NORDISK WILL ACQUIRE FROM STRONGBRIDGE BIOPHARMA PLC ITS RIGHTS TO MACRILEN IN UNITED STATES AND CANADA.AETERNA ZENTARIS INC - HAS LICENSED RIGHTS TO MACRILEN™ IN UNITED STATES AND CANADA TO STRONGBRIDGE BIOPHARMA.  Full Article

Novo Nordisk CEO Says To Double UK Inventories Ahead Of Potential Hard Brexit
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - Novo Nordisk A/S CEO Lars Fruergaard Jorgensen said on Thursday::NOVO NORDISK CEO SAYS WITH REGARDS TO BREXIT WE WILL MAKE SURE WE HAVE MORE THAN DOUBLED OUR INVENTORIES IN THE UK BY THE TIME OF A POTENTIAL HARD BREXIT.NOVO NORDISK CEO SAYS NO PLANS FOR FURTHER MEASURES WITH REGARDS TO LAY-OFFS IN 2019.  Full Article

Novo Nordisk Q3 Ebit Slightly Below Forecast
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - NOVO NORDISK A/S ::Q3 EBIT 11,813 MILLION DKK VERSUS 11,934 MILLION DKK SEEN IN REUTERS POLL.9-MONTH SALES 82.1 BILLION DKK VERSUS 81.9 BILLION DKK SEEN IN REUTERS POLL.NOVO NORDISK'S OPERATING PROFIT DECREASED BY 6% IN DANISH KRONER AND INCREASED BY 2% IN LOCAL CURRENCIES IN THE FIRST NINE MONTHS OF 2018.NOW SEES FOR 2018, SALES GROWTH IS NOW EXPECTED TO BE 4-5% AND OPERATING PROFIT GROWTH IS STILL EXPECTED TO BE 2-5%, BOTH MEASURED IN LOCAL CURRENCIES.SAYS GROWTH REPORTED IN DANISH KRONER IS NOW EXPECTED TO BE 4 PERCENTAGE POINTS LOWER THAN IN LOCAL CURRENCIES WHILE OPERATING PROFIT GROWTH IS STILL EXPECTED TO BE 7 PERCENTAGE POINTS LOWER THAN IN LOCAL CURRENCIES.SALES OF VICTOZA(®) INCREASED BY 6% TO DKK 17.8 BILLION.SALES OF OZEMPIC(®) WERE DKK 804 MILLION AND TOTAL GLP-1 FRANCHISE INCREASED 10%.SAYS BASED ON INCREASED EXPECTATIONS FOR CASH FLOW GENERATION IN 2018, BOARD OF DIRECTORS HAS APPROVED AN EXPANSION OF 2018 SHARE REPURCHASE PROGRAMME WITH DKK 1.0 BILLION TO DKK 15 BILLION.9-MONTH OPERATING PROFIT 36.5 BILLION DKK VERSUS 36.6 BILLION DKK SEEN IN REUTERS POLL.CEO SAYS WE ARE OFF TO A VERY GOOD START WITH OZEMPIC(®) WHICH IS STRENGTHENING OUR LEADERSHIP POSITION IN EXPANDING GLP-1 MARKET.SAYS A NUMBER OF ADDITIONAL RESTRUCTURING INITIATIVES ACROSS FUNCTIONS AND GEOGRAPHIES HAVE BEEN INITIATED TO SUPPORT COMMERCIAL ACTIVITIES FOR PORTFOLIO OF INNOVATIVE PRODUCTS.  Full Article

Novo Nordisk Pioneer 8 Trial Of Oral Semaglutide Achieved Primary Objective
Friday, 26 Oct 2018 

Oct 26 (Reuters) - NOVO NORDISK A/S PRESENTS RESULTS OF PIONEER 8 TRIAL::NOVO NORDISK TODAY ANNOUNCED THE HEADLINE RESULTS FROM PIONEER 8, A PHASE 3A TRIAL WITH ORAL SEMAGLUTIDE FOR THE TREATMENT OF ADULTS WITH TYPE 2 DIABETES.ORAL SEMAGLUTIDE DEMONSTRATES STATISTICALLY SIGNIFICANT REDUCTIONS IN HBA1C AND BODY WEIGHT IN PEOPLE WITH LONG DURATION OF TYPE 2 DIABETES TREATED WITH INSULIN.PIONEER 8 TRIAL ACHIEVED ITS PRIMARY OBJECTIVE BY DEMONSTRATING STATISTICALLY SIGNIFICANT AND SUPERIOR REDUCTIONS IN HBA(1C) AND BODY WEIGHT WITH ALL THREE DOSES OF ORAL SEMAGLUTIDE COMPARED TO PLACEBO.WHEN APPLYING THE PRIMARY STATISTICAL APPROACH, THE TRIAL ACHIEVED ITS PRIMARY OBJECTIVE BY DEMONSTRATING STATISTICALLY SIGNIFICANT AND SUPERIOR REDUCTIONS IN HBA1C AND BODY WEIGHT WITH ALL THREE DOSES OF ORAL SEMAGLUTIDE COMPARED TO PLACEBO, ALL IN ADDITION TO INSULIN, AT WEEK 26.WHEN APPLYING THE SECONDARY STATISTICAL APPROACH, FROM A MEAN BASELINE OF 8.2%, PEOPLE TREATED WITH 3, 7 AND 14 MG ORAL SEMAGLUTIDE ACHIEVED REDUCTIONS IN HBA1C OF 0.6%, 1.0% AND 1.4% RESPECTIVELY, COMPARED TO NO REDUCTION (0.0%) IN PEOPLE TREATED WITH PLACEBO, ALL IN ADDITION TO INSULIN, AT WEEK 26, AND 0.5%, 0.8% AND 1.2% RESPECTIVELY, COMPARED WITH 0.0% AT WEEK 52.  Full Article

Novo Nordisk Announced U.S. FDA Approved An Updated Label For Saxenda Injection 3 Mg
Monday, 22 Oct 2018 

Oct 22 (Reuters) - :NOVO NORDISK ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVED AN UPDATED LABEL FOR SAXENDA® (LIRAGLUTIDE) INJECTION 3 MG.  Full Article

Novo Nordisk To Establish California Manufacturing Site For Stem Cell-Based Therapies
Monday, 1 Oct 2018 

Oct 1 (Reuters) - NOVO NORDISK A/S SAYS::WILL ESTABLISH CALIFORNIA MANUFACTURING SITE FOR STEM CELL-BASED THERAPIES.ANNOUNCED THE ESTABLISHMENT OF A MANUFACTURING SITE IN FREMONT, CALIFORNIA, US TO DEVELOP AND PRODUCE STEM CELL-BASED THERAPIES."OUR AMBITION IS TO DEVELOP STEM CELL-BASED THERAPIES FOR A RANGE OF SERIOUS CHRONIC DISEASES WHERE WE SEE SIGNIFICANT UNMET MEDICAL NEED," SAYS JACOB STEN PETERSEN, CORPORATE VICE PRESIDENT AND HEAD OF STEM CELL RESEARCH & DEVELOPMENT (R&D), NOVO NORDISK. ."THE RELIABLE, LARGE-SCALE SUPPLY OF THERAPIES IS A VITAL COMPONENT IN OUR EFFORTS, SO I AM DELIGHTED THAT WE HAVE ESTABLISHED THIS FACILITY THAT FURTHER DEMONSTRATES OUR STRONG COMMITMENT TO THIS FIELD.".ONCE OPERATIONAL IN 2019, FACILITY WILL FULFIL SUPPLY OF STEM CELL-BASED THERAPIES FOR NOVO NORDISK'S CLINICAL TRIAL PROGRAMMES.HAS SECURED A TWO-YEAR NON-EXCLUSIVE LICENCE ON ASTERIAS' INTELLECTUAL PROPERTY RELATING TO STEM CELL MANUFACTURING TECHNOLOGY.  Full Article

Novo Nordisk Says New Phase 2 Data For Somapacitan Demonstrate Its Potential
Friday, 28 Sep 2018 

Sept 28 (Reuters) - Novo Nordisk A/S ::NOVO NORDISK A/S - NEW PHASE 2 DATA FOR SOMAPACITAN DEMONSTRATE ITS POTENTIAL AS AN EFFICACIOUS ONCE-WEEKLY TREATMENT FOR CHILDHOOD GROWTH HORMONE DEFICIENCY.  Full Article

Novo Nordisk Canada Says Quebec To Provide Public Funding Of Tresiba
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - Novo Nordisk A/S ::NOVO NORDISK CANADA - QUEBEC GOVERNMENT TO PROVIDE PUBLIC FUNDING OF TRESIBA, AN INSULIN FOR TREATING ADULTS LIVING WITH TYPE 1 AND TYPE 2 DIABETES.  Full Article

Danish Govt, Novo Nordisk to partner with UN-anchored initiative on non-communicable diseases
Monday, 24 Sep 2018 

Sept 24 (Reuters) - Novo Nordisk A/S ::DANISH GOVERNMENT, NOVO NORDISK ANNOUNCING GRANTS OF 3 AND 5 MILLION US DOLLARS RESPECTIVELY TO NEWLY ESTABLISHED DEFEAT-NCD PARTNERSHIP DURING LAUNCH EVENT AT UNGA.  Full Article

Photo

Patients and industry fret over drug supplies, if no Brexit deal

LONDON Consumers and the pharmaceuticals industry alike are anxious about medicine supplies, if there is no deal on Britain's departure from the European Union.